Understanding the impact of a rare disease – the Health Heroes podcastEpisode one of Kantar’s Health Heroes podcast looks at caregiving challenges for Gaucher disease and how patient registries Share XUnderstanding the impact of a rare disease – the Health Heroes podcasthttps://pharmaphorum.com/podcast/health-heroes-podcast-rare-disease-impact/
Podcast series to spotlight health heroes launched by KantarA new pharmaceutical podcast putting health heroes in the spotlight debuts in the runup to Rare Diseases Day Share XPodcast series to spotlight health heroes launched by Kantarhttps://pharmaphorum.com/news/podcast-series-to-spotlight-health-heroes-launched-by-kantar/
Engaging the empowered patientSuccess requires addressing behaviour from the individual’s perspective, as well as a socio-cultural and environmental context, says Andy Share XEngaging the empowered patienthttps://deep-dive.pharmaphorum.com/magazine/patient-engagement/engaging-the-empowered-patient-kantar/
Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Did cancer clinical trials stay on track at ASCO 2019?Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. Share XDid cancer clinical trials stay on track at ASCO 2019?https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/kantar-cancer-clinical-trials/
ASCO 2019 round-upWith the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share XASCO 2019 round-uphttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 day fiveExclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago. • Share XASCO 2019 day fivehttps://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-five/
